Start with the latest dated revenue
The reported-period revenue series records CAD 1.39m for the period ended June 30, 2026.
—
—
—
Pharmacielo Ltd.
—
—
Live Price
CIN RESEARCH · DATED EVIDENCE
Dated financial evidencePharmacielo Ltd.: review the dated company evidence.
The reported-period revenue series records CAD 1.39m for the period ended June 30, 2026. Cash and operating cash flow are available on a matching dated basis.
Latest financial observation 2026-06-30Last reported price 2026-11-05Research checked 2026-11-06 13:30 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Revenue and profitability are separate
The matching reported-period net loss is CAD 1.44m. This is the reported result for 2026-06-30, not a future earnings estimate.
Put cash beside operating cash flow
Period-end cash was CAD 77,498 at 2026-06-30. The matching reported-period operating cash outflow was CAD 227,861. Later financing and cash movements are not established by this snapshot.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| Revenue | CAD 1.39mUnit: CAD | Quarterly series | Dated financial series |
| Cost of revenue | CAD 871,892Unit: CAD | Quarterly series | Dated financial series |
| Gross profit | CAD 518,185Unit: CAD | Quarterly series | Dated financial series |
| Operating income | CAD -727,811Unit: CAD | Quarterly series | Dated financial series |
| EBITDA | CAD -661,304Unit: CAD | Quarterly series | Dated financial series |
| Net income | CAD -1.44mUnit: CAD | Quarterly series | Dated financial series |
| Cash balance | CAD 77,498Unit: CAD | Balance at period end | Dated financial series |
| Total assets | CAD 12.75mUnit: CAD | Balance at period end | Dated financial series |
| Total liabilities | CAD 23.44mUnit: CAD | Balance at period end | Dated financial series |
| Shareholders’ equity | CAD -10.7mUnit: CAD | Balance at period end | Dated financial series |
| Operating cash flow | CAD -227,861Unit: CAD | Quarterly series | Dated financial series |
| Free cash flow | CAD -227,861Unit: CAD | Quarterly series | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Read the latest linked company disclosures and any reporting after the financial period.
- Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- No dated primary company disclosures were supplied; absence in this feed is not a clean regulatory check.
- Interim frequency is provider-classified. Generic form labels are not treated as proof of an SEC filing or a three-month reporting duration.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · CAD
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH